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ABSTRACT OF THE THESIS
Tests, Tests, and More Tests: A New Era for Dementia Diagnosis
by
Jonathan Gooblar
Master of Arts in Psychology
Washington University in St. Louis, 2013
Professor Brian D. Carpenter, Chair
Cerebrospinal fluid (CSF) proteins correlate with pathological changes that are hallmarks
of Alzheimer’s disease (AD). CSF biomarkers have been used in research settings to predict AD
diagnosis and rate of cognitive decline, however their use in clinical settings is limited. Given
their potential utility in identifying preclinical AD and in increasing diagnostic confidence in
clinical settings, we sought to understand how clinicians use CSF biomarkers in conjunction with
other clinical details to diagnose AD. Participants (N = 193) were physicians and other medical
professionals who routinely evaluate older adults for neurodegenerative disease. In a withinsubjects factorial design, participants were randomized and viewed normal, borderline, ADconsistent, or no CSF information along with two clinical vignettes portraying patients with
borderline and mild AD symptoms. In addition, clinicians reported on their use and the utility of
CSF lab results in clinical practice. Clinicians reported infrequent use and limited utility of CSF
biomarkers in clinical practice, yet CSF biomarkers affected clinical decisions on two vignettes.
AD-consistent CSF values made clinicians 6-12 times more likely to make an AD-related
diagnosis, increased diagnostic confidence, and led clinicians to initiate treatment more often
than other CSF values. Furthermore, clinicians relied on CSF evidence more heavily when ADconsistent CSF values were presented in the context of a borderline case of memory impairment.
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In sum, CSF biomarkers have a significant impact on clinical decisions, and show different
effects depending on contextual factors. Therefore, as CSF biomarkers become more widespread
in clinical practice, clinicians should consider the potentially significant effect of biomarkers on
their clinical decisions.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia in the United States,
and if left untreated is expected to affect nearly 14 million people by the year 2050 (Hebert,
Weuve, Scherr, & Evans, 2013). AD is widely conceptualized as a clinical and pathological
process, encompassing memory impairment and functional decline as well as brain changes such
as neurofibrillary tangles and amyloid plaques (Dubois et al., 2010). Clinical tools commonly
used to assess patients with memory complaints who may have AD range from
neuropsychological testing and functional assessments to laboratory blood analysis and
neuroimaging. Increasingly, cerebrospinal fluid (CSF) biomarkers shown to correlate with AD
pathological changes have been used in research settings to evaluate cases of suspected incipient
AD, discriminate among different etiologies, predict rate of disease progression, and track
pathological changes in clinical trials (Blennow, 2005; Snider et al., 2009; Toledo et al., 2012).
However, recent practice guidelines have not endorsed the use of CSF biomarkers in clinical
settings, citing the need for further research on laboratory standardization of biomarker
measurements and interpretation of indeterminate biomarker results (McKhann et al., 2011).
Furthermore, it is unclear how clinicians would interpret CSF information in conjunction with
other clinical details in clinical practice (Zetterberg, Lunn, & Herukka, 2012). As CSF
biomarkers become more widespread in clinical practice, we sought to evaluate their influence
on clinical dementia evaluations and to understand how clinicians interpret CSF information in
various clinical contexts. In this study, we employed a vignette-based survey with clinicians who
evaluate older adults to examine the impact of CSF biomarker information on diagnostic
decisions, diagnostic confidence, and treatment choices for two hypothetical patients with
memory complaints.
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The role of CSF information in clinical dementia assessment is evolving. While CSF
biomarkers are widely used in research settings and have shown good predictive ability for AD
diagnosis, their use in clinical settings is limited (Blennow & Zetterberg, 2009). Concerns about
laboratory standardization and potential for conflicting or ambiguous CSF values have kept
biomarker tests from widespread clinical use (McKhann et al., 2011). Furthermore, the
possibility of identifying pathological processes in clinically normal individuals raises ethical
issues given a lack of meaningful treatment options for dementia. Yet, CSF biomarkers could
play an important role in clarifying ambiguous cases, discriminating among the dementias, and
predicting progression of cognitive impairment and dementia (Snider et al., 2009; Tabaraud et
al., 2012; Zetterberg et al., 2012). A recent study addressing concerns about unreliable crosslaboratory measurements concluded that locally standardized procedures could increase the
reliability and usefulness CSF measures (Mattson et al., 2012). Importantly, early reliable
diagnosis of AD could be necessary for preventative treatment, and could give comfort to
patients and families who are eager to understand possible causes of cognitive decline.
It remains unknown, however, how clinicians might use CSF biomarker information in
clinical practice. Previous studies have examined the utility of CSF information in research
settings, finding good diagnostic sensitivity and correlation with pathological markers of AD
progression such as structural brain changes (Blennow, 2005; Fagan et al., 2009). Other studies
have supported the utility of CSF biomarkers in identifying AD pathology in preclinical and MCI
populations, and in older adults with suspected AD (Mattson et al., 2012; Parnetti, Lanari,
Silvestrelli, Saggese, & Reboldi, 2006; Stomrud, Hansson, Blennow, Minthon, & Londos, 2007).
No research to our knowledge, however, has surveyed clinicians to examine how CSF
information might be used in conjunction with other clinical details to diagnose dementia.
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Furthermore, no previous studies to our knowledge have evaluated the utility of CSF biomarkers
in combination with other clinical details in evaluating patients with memory complaints.
In this study, we presented clinicians with two clinical vignettes to illustrate a typical
ambiguous and mild-AD presentation in a clinic or hospital. Clinical vignettes are a valuable,
cost-effective research method for understanding professional judgment of multiple clinical
factors while mirroring plausible real-world scenarios (Veloski, Tai, Evans, & Nash, 2005).
Clinicians, including physicians, nurse practitioners, physician assistants, and advanced practice
nurses, were randomized into one of four groups according to the type of CSF biomarker
information they viewed. Three of the groups viewed CSF values consistent with normal,
borderline, or AD patient presentations, while the fourth group did not view any CSF
information embedded in the vignettes. Given previous studies about the utility of CSF
information in research settings, we hypothesized that biomarker values would influence
diagnosis, diagnostic confidence, and treatment planning. In addition, we assessed demographic
factors, clinician use of and confidence in clinical tools for assessing patients with memory
impairment, and clinician evaluation of clinical details in the vignettes.

Method
Participants
Recruitment. Physicians (MD and DO), nurse practitioners and advanced practice nurses
(NP and APRN), and physician assistants (PA) were eligible for the study if they routinely
evaluate patients over age 65. We targeted academic and nonacademic clinicians and recruited
from primary care, internal medicine, neurology, geriatrics, and geriatric psychiatry. Potential
participants were contacted using publicly available e-mail addresses on university and medical
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center websites and professional organization e-mail lists and public contact information.
Between January and July, 2013, we distributed recruitment e-mails describing the scope of the
study and including a link to the questionnaire, which was hosted by Qualtrics, a secure online
survey platform. Informed consent was obtained from all participants in the study, which was
approved by the Washington University Human Research Protection Office.
Sample size. Based on a desired power of .8, alpha set at .05, and a conventional medium
effect size, G*Power suggested a required sample size of 192 to perform chi-square analyses
(Cohen, 1988; Faul, Erdfelder, Lang, & Buchner, 2009). Out of 291 individuals who began the
questionnaire, 248 respondents were eligible to participate and were randomized into conditions
in the study. A total of 193 participants completed the entire questionnaire, while 55 partially
completed the questionnaire. Completers and partial completers were statistically similar in
terms of age, years in clinical practice, approximate percentage of patients seen over the age of
65, practice specialty, and practice setting.
Materials
The study design and materials (details below) were developed by a team of investigators
representing neurology, nursing, clinical psychology, and social work. We pilot tested the
questionnaire with 10 clinicians at the Knight Alzheimer’s Disease Research Center and revised
it for clarity based on their feedback. The questionnaire included demographic and clinical
practice questions, one page of education materials about CSF biomarkers for diagnosing AD,
and two clinical vignettes with follow-up diagnostic questions.
Demographic and practice questions and randomization. At the start of the
questionnaire, participants completed a series of demographic and professional background
questions. If they met inclusion criteria, participants were randomized into one of four

4

experimental groups according to the type of CSF information they viewed with each of two
clinical vignettes, consistent with a 2 x 4 within-subjects factorial design. Participants in groups
1, 2, and 3 were shown normal, borderline, or AD-consistent CSF values, respectively, with each
vignette, while participants in group 4 were not shown any CSF information. After
randomization, participants responded to clinical practice questions (i.e., how often they collect,
and how useful they find, various diagnostic tests for cognitive impairment). Figure 1 outlines
randomization and procedural flow.
CSF education. We developed a one-page education sheet outlining the clinical use of
CSF biomarkers in identifying AD pathology (see Appendix A). This information was presented
directly before the two clinical vignettes and contained sensitivity and specificity information for
Aβ42, ttau, ptau, and the ratio between Aβ42 and ttau, which usually provides the best
classification information for people with and without AD pathology (Fagan et al., 2007). The
education sheet noted the limitations of these data due to overlap between diagnostic groups and
the fact that CSF values indicate pathological, and not necessarily symptomatic, changes (Price
et al., 2009; Price & Morris, 1999).
Clinical vignettes. The two vignettes included information about age, gender, memory,
functional status, mood, subjective complaints, and an informant report (see Appendix B). One
vignette described a borderline or unclear case with ambiguous presenting symptoms, and the
second described a patient with symptoms consistent with mild AD. Embedded in the vignettes
were Aβ42, ttau, ptau, and ratio values consistent with each CSF condition (normal, borderline, or
AD consistent), for participants randomized to receive CSF information. The order of the
vignettes was counterbalanced across participants.
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After each vignette, participants chose a diagnosis from a list of six options (normal/no
diagnosis, mild cognitive impairment (MCI) due to unknown causes, MCI due to AD, AD
dementia, memory loss due to uncertain causes, or depression); rated their diagnostic confidence
on a scale from 1 (not at all confident), 3 (moderately confident), to 5 (very confident); and
indicated their recommendation for treatment, if any, in an open-ended response. Next,
participants were asked whether each clinical detail in the vignette (i.e., age, gender, memory,
functional status, mood, informant report, CSF values) made them less or more confident in their
diagnosis on a 5-point Likert-type scale: 1 (less confident), 3 (neither less nor more confident), 5
(more confident). Finally, participants were asked in an open-ended question what additional
clinical details they would have liked in order to evaluate each vignette. While answering these
questions, participants were able to view the relevant vignette and the CSF education page.
Data analysis
Statistical analyses were conducted in three phases using SPSS (version 21). First,
descriptive statistics of demographic and practice information were calculated in order to
examine sample characteristics. Second, chi-squares, t-tests, and analyses of variance were
conducted in order to evaluate whether CSF information was related to diagnostic choices,
diagnostic confidence, and treatment plan. Finally, a series of logistic regressions were
conducted to model multivariate associations between clinician diagnosis and CSF group
assignment, demographic and practice variables, and clinical detail ratings.
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Results
Demographic and practice information
Table 1 summarizes demographic information for the sample. Respondents were mostly
physicians (90%), although the non-MD clinicians did not differ from the physicians on any
demographic or practice characteristics and were therefore included in the final sample to
represent the diversity of clinicians evaluating and treating patients with neurodegenerative
disease in the United States. Overall, participants reported a variety of practice specialties and
were experienced in caring for older adults.
In terms of their practice behaviors, clinicians reported frequent use of cognitive
screening tests and neuroimaging, moderate use of comprehensive cognitive testing, and
infrequent use of metabolic and CSF tests (see Table 2). In terms of perceived utility, cognitive
screening and comprehensive examinations were rated as very useful by most clinicians, whereas
fewer respondents agreed on the utility of neuroimaging, and few clinicians rated metabolic or
CSF testing as useful for diagnosing dementia. Significant differences were notable across
practice specialties. Neurologists reported greater use of cognitive testing, neuroimaging, and
lumbar puncture as compared to geriatricians and nonspecialists such as primary care and
internal medicine clinicians. Neurologists also reported finding neuroimaging and lumbar
puncture more useful than did nonspecialists and geriatricians.
Does the presence of any type of CSF information influence clinical decisions?
In order to examine the effect of CSF information on diagnostic decisions, we
consolidated diagnostic categories from the questionnaire to eliminate small cell sizes and to
reflect our interest in clinician choice of underlying etiology (AD-consistent or unknown
etiology) rather than in diagnostic labels that may vary across practice specialty or setting. The
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presence of CSF information was significantly related to diagnostic choices for the borderline
vignette, χ2(1, N = 165) = 9.09, p = .003, but not for the AD vignette, χ2(1, N = 187) = 0.19, p =
.67. Clinicians who received CSF information of any type were more likely to make an ADrelated diagnosis than clinicians who did not receive CSF information (47% compared to 22%; z
= 3.0, p < .01).
Diagnostic confidence ratings are detailed in Table 3. Clinicians who had CSF
information with the AD vignette, but not the borderline vignette, rated their diagnostic
confidence significantly higher than clinicians who did not have CSF information, t(191) = 2.83,
p = .005. Furthermore, clinicians who chose an AD-related diagnosis on the AD vignette and had
CSF information reported higher diagnostic confidence than clinicians who made the same
diagnosis but did not have CSF information, t(96) = 2.03, p = .045. In other words, even when
making a similar diagnosis with otherwise identical clinical information, clinicians reported
higher diagnostic confidence when they had CSF information.
Regarding treatment decisions, clinicians who had CSF information were more likely to
suggest initiating treatment on the borderline vignette, χ2(1, N = 161) = 9.31, p = .002, but not on
the AD vignette, χ2(1, N = 161) = 1.07, p = .30. While most clinicians (70.8%) chose not to
treat, those who had CSF information were more likely to initiate treatment (35.9%) in the
borderline vignette compared to those who did not have CSF information (11.4% z = 3.1, p <
.01).
Do particular CSF protein values influence clinical decisions?
Type of CSF information (normal, borderline, AD-consistent, or no CSF protein values)
was related to clinician diagnosis for both the borderline and the AD vignette, as detailed in
Figure 2. For both vignettes, the diagnosis chosen by clinicians depended, in part, on the CSF
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values presented. When given normal CSF values, few clinicians made an AD-related diagnosis
(19.4% for the borderline vignette, 27.3% for the AD vignette). The proportion of clinicians
assigning a diagnosis related to AD was higher when they received borderline CSF values (41%
for the borderline vignette, 47.7% for the AD vignette), and higher still when they received ADconsistent CSF values (77.5% for the borderline vignette, 86% for the AD vignette). Clinicians
who did not receive CSF information assigned diagnoses in equal numbers for the AD vignette,
while most clinicians (78%) diagnosed unknown etiology for the borderline vignette.
Regarding diagnostic confidence, there was a significant effect of CSF group on
confidence ratings for both vignettes (for the borderline vignette, F(3,188) = 4.05, p = .008; for
the AD vignette, F(3,189) = 5.66, p = .001). On the borderline vignette, clinicians who received
AD-consistent CSF values were significantly more confident in their diagnosis compared to
clinicians who did not view CSF information (see Table 3). On the AD vignette, clinicians who
received AD-consistent CSF values were more confident in their diagnosis than clinicians who
viewed borderline CSF values or no CSF information. In addition, clinicians who made an ADrelated diagnosis on the AD vignette and had AD-consistent information reported the highest
diagnostic confidence compared to clinicians with borderline or no CSF information, F(3,94) =
3.96, p = .01.
There was a significant effect of CSF values on the decision to treat for the borderline
vignette, χ2(3, N = 161) = 13.44, p = .004, but not for the AD vignette, χ2(3, N = 161) = 6.61, p =
.086. Although most clinicians (70.8%) chose not to start treatment in the borderline vignette,
clinicians who had AD-consistent CSF were significantly more likely to treat than those who had
borderline or normal CSF values (48.5% versus 35% and 27.3%, respectively; z = 2.7, p < .01).
On the AD vignette, adjusted residual scores indicated that clinicians receiving AD-consistent

9

CSF were more likely to initiate treatment than clinicians who received borderline or normal
CSF values (58.8% versus 35.9% and 34.9%, respectively; z = 2.6, p < .01), although the
omnibus chi-square test was not significant and this result should be interpreted with caution.
Finally, a series of binary logistic regression models were evaluated to determine whether
clinician demographic variables, CSF group assignment, and post-vignette responses predicted
diagnostic choices (AD etiology versus unknown etiology; see Table 4). The most parsimonious
models included CSF group as the only significant predictor variable for the borderline vignette,
and CSF group and post-vignette confidence rating of the informant report as significant
predictors of diagnosis on the AD vignette (see Table 4). For both vignettes, receiving ADconsistent CSF values led to increased odds of choosing an AD-related diagnosis, while
clinicians who rated the informant report as valuable in forming a diagnosis were more likely to
choose an AD diagnosis on the AD vignette (but not the borderline vignette). Variables that were
not significant predictors of diagnostic choices included demographic factors (years in practice,
percentage of patients over age 65, and practice specialty), practice questions related to lumbar
puncture use, and post-vignette clinical measure ratings (aside from informant report).
Confidence ratings of clinical measures and preference for additional tests
Following each vignette, participants rated whether clinical details that appeared in the
vignette made them less or more confident in their diagnosis. Clinicians reported high diagnostic
confidence ratings for collateral information from a family member and patient functional status,
while patient age and CSF information were rated as least useful in formulating a diagnosis (see
Table 5). In addition, post-vignette CSF ratings differed significantly from initial clinical practice
questions. Clinicians rated CSF information included in the vignettes as significantly more useful
compared to ratings of CSF biomarker utility in their clinical practice (for the borderline
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vignette, M = 3.22 vs. 2.19, t(130) = 1.03, p < .001; for the AD vignette, M = 3.36 vs. 2.20,
t(128) = 1.16, p < .001).
Furthermore, post-vignette ratings of CSF utility depended in part on CSF group (for the
borderline vignette, F(2, 132) = 5.99, p = .003; for the AD vignette, F(2, 130) = 8.37, p < .001).
Tukey post-hoc tests showed that clinicians receiving AD-consistent CSF values on the
borderline vignette rated CSF information as more useful than did clinicians who received
borderline CSF values (M = 3.58 vs. M = 2.93). Clinicians who received AD-consistent CSF
values on the AD vignette rated CSF information as more useful than did clinicians who received
normal or borderline CSF values (M = 3.84 vs. normal CSF, M = 3.15 and vs. borderline CSF, M
= 3.11). Taken together, these results indicate that while clinicians rated collateral reports and
functional status as the most helpful clinical tools in formulating a diagnosis, viewing ADconsistent CSF values provided a similar level of diagnostic confidence and they were rated as
more helpful than borderline or normal CSF values.
Finally, clinicians indicated which additional diagnostic tests they would have found
useful in formulating a diagnosis in an open-ended response. For both vignettes, 25-30% of
clinicians requested neuroimaging, neuropsychological testing, and laboratory information such
as blood analysis. Fewer clinicians (approximately 15%) indicated that brief neuropsychological
screening or a depression evaluation would have been useful. Clinicians also described a wide
variety of additional information they would have collected. Some clinicians indicated that
additional testing was required to arrive at a diagnosis (e.g., “Really must have cognitive testing
as well.”). Others wrote that they would like longitudinal follow-up information as well as
medical history. About 20% of participants requested one additional test, and another 20% each
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requested two or three additional tests. Others (14% for the borderline vignette, 18% for the AD
vignette) did not request any additional information.
Discussion
This study is one of the first to examine how clinicians use CSF biomarkers in
combination with other clinical information to diagnose cognitive impairment. Participants
responded to practice questions and evaluated two vignettes describing patients with ambiguous
borderline symptoms and with mild memory complaints. While clinicians reported infrequent
use and limited utility of CSF biomarkers in their current clinical practice, the inclusion CSF
information influenced diagnosis, diagnostic confidence, and the decision to treat. Taken
together, these results highlight the influence of CSF biomarkers on clinical decisions, even
when that information is weighed alongside other clinical details routinely reported as more
useful in clinical practice. Examining these findings more closely, a number of trends are
apparent.
First, results from this study suggest that holding CSF information makes clinicians more
likely to assign an AD-related diagnosis, increases diagnostic confidence, and influences the
decision to treat. Overall, clinicians who had CSF information of any type were more than twice
as likely to make an AD-related diagnosis and were more likely to initiate treatment on a
borderline case. In addition, clinicians who had CSF information reported significantly higher
diagnostic confidence on a mild AD vignette. In sum, these results suggest that merely viewing
CSF information of any type affects clinical decisions regardless of the particular protein values.
It is notable that these effects were driven by clinicians who had borderline and AD-consistent
CSF values, which could suggest that evaluating the impact of all three CSF groups together may
not be meaningful. However, protein values are continuous measures, and therefore these effects
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may apply to the virtually infinite combinations of CSF protein values clinicians are likely to
encounter in clinical practice.
Second, as CSF values increasingly reflected AD pathology, clinicians made AD-related
diagnoses with increasing frequency and with greater confidence (see Figure 2). Clinicians who
viewed normal CSF values disproportionately made diagnoses with unknown etiology, while
most clinicians who viewed AD-consistent CSF values made AD-related diagnoses.
Furthermore, the proportion of clinicians choosing to initiate treatment on the borderline vignette
rose as CSF values increasingly pointed to AD pathology (27.3%, 35%, and 48.5% for normal,
borderline, and AD CSF values, respectively). Finally, clinicians with AD-consistent CSF values
reported the highest diagnostic confidence compared to clinicians with other types of CSF data.
As such, AD-consistent CSF biomarkers may exert a confirmatory effect relative to more
familiar, established clinical details with which clinicians currently have more experience.
Third, ambiguous CSF values had little effect on clinical decisions. Clinicians who
viewed borderline CSF information made unknown etiology and AD-related diagnoses in
relatively equal frequency, suggesting that CSF information had no effect on diagnosis for these
participants. Moreover, the decision to initiate treatment was not significantly different between
clinicians who viewed normal or borderline CSF values on the AD vignette, suggesting that
values showing relatively increased risk for AD pathology (i.e., borderline CSF values) did not
affect treatment planning. Current practice guidelines and diagnostic criteria for AD do not
endorse use of CSF biomarkers in part because of the potential for indeterminate biomarker
values (McKhann et al., 2011). Furthermore, Zetterberg and colleagues (2012) caution that
clinicians may misinterpret CSF biomarker results as definitive, without considering the entire
clinical picture. The results of this study suggest that when presented with ambiguous or
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indeterminate CSF values, clinicians rely on other clinical details to make diagnostic and
treatment decisions.
Fourth, inconsistent pathological and clinical information affects clinical decisions.
Clinicians who viewed normal CSF values in a vignette that included other clinical details
consistent with AD most often chose a diagnosis with unknown etiology. In contrast, clinicians
who viewed AD-consistent CSF values in a vignette that included other ambiguous clinical
details were swayed by those CSF values and made an AD-related diagnosis. In sum, clinicians
appear to give less weight to CSF biomarkers when they are in the normal range, and greater
weight when they are consistent with AD pathology, even when paired with ambiguous clinical
details. Furthermore, on the borderline vignette, clinicians who had AD-consistent CSF
information were 12 times more likely to make an AD-related diagnosis than clinicians who did
not have CSF information. In contrast, the same comparison was relatively muted for the AD
vignette, in part because clinicians who did not have CSF information made unknown etiology
and AD-related diagnoses in equal numbers. In terms of treatment, CSF values affected the
decision to initiate treatment in the borderline vignette, whereas this effect was questionable for
the AD vignette. Taken together, in the setting of borderline clinical details, AD-consistent CSF
values are likely to be more impactful on diagnosis and treatment planning, whereas the same
values had less effect on clinical decisions in a mild AD case.
These findings suggest that clinicians do not view CSF values in a vacuum, but consider
their utility in combination with other clinical details to make decisions. Clinician reports on the
use and the utility of clinical tools shed light on how evaluations are currently conducted, and
how they might evolve as CSF testing becomes more widespread in clinical settings. Overall,
reported use of neuropsychological screening and testing, neuroimaging, and lumbar puncture
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were consistent with current practice guidelines for evaluating patients with memory complaints
(McKhann et al., 2011). However, there were variations in ratings of use and utility of each tool
and significant differences between practice specialties, suggesting the lack of standardization in
dementia assessment. Neurologists report the greatest use and utility of cognitive assessments
and neuroimaging. In contrast, nonspecialists in solo private practice or smaller clinics may rely
more heavily on clinical history due to limited resources or specialized training. Heterogeneity in
assessment techniques was also apparent in response to the vignettes. While a quarter of the
sample agreed that neuropsychological testing, neuroimaging, and laboratory values would have
been useful as part of the vignettes in forming a diagnosis, there were many infrequent
responses. Only 16% of clinicians requested medical history or follow-up visit information, and
only 6% mentioned the importance of exploring potentially reversible causes of dementia, all of
which are recommended according to current practice guidelines (McKhann et al., 2011). Future
studies might examine how clinicians assess CSF information in combination with additional
common clinical measures or as part of potential future clinical practice criteria.
This study was the first, to our knowledge, to examine how clinicians use CSF
information to diagnose dementia. A number of limitations, however, should be acknowledged.
First, the vignettes were brief in order to encourage participation among busy clinicians and
lacked the more extensive detail that some clinicians might have access to in practice. Future
studies could include additional test results, such as neuropsychological test scores, MRI reports,
and functional assessments, and examine how various combinations of results influence clinical
decision-making. More extensive vignettes comprised of formal diagnostic criteria could allow
for a more complete understanding of the function of CSF information within current practice
guidelines. Furthermore, future studies could incorporate factors likely to be present in deciding
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to order CSF testing, such as cost and patient willingness. Second, our sample disproportionately
included physicians employed in academic medical centers, whose familiarity with CSF values
may differ from clinicians in private practice. Therefore, although we obtained some
heterogeneity in our sample, which also included non-physicians, the generalizability of our
results may be limited. Third, we were not able to examine the effect of CSF values on specific
diagnoses due to small cell sizes, nor did this study assess the utility of biomarkers in differential
diagnosis across the dementias. Given that CSF biomarkers have been useful for differential
diagnosis of dementia in research settings, it is important to understand how CSF information
would influence decision-making for varied patient presentations.
Despite these limitations, this study suggests that CSF values impact clinical decisions,
even while clinicians do not view them as especially useful. CSF information is likely to become
more widely used in clinical practice in the years ahead, particularly as clinicians attempt to
identify preclinical cases for early intervention. This study represents a first step in exploring the
potential role of CSF biomarkers in clinical evaluations, and in understanding how clinicians
integrate clinical and pathological information to make clinical decisions.
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Table 1
Participant Characteristics (N =193)
Characteristic
M/n
SD/%
Sex
Male
102
53
Female
84
44
Unspecified
7
4
Age
50.98
10.80
Race/Ethnicity
White
153
79
Asian
22
11
Hispanic, Latino, Spanish
6
3
Black or African American
4
2
Other
8
6
Degree
MD
175
90
DO
7
4
NP
7
4
APRN
2
1
PA
2
1
Practice specialty
Neurology
93
48
Geriatrics
59
31
Internal medicine
15
8
Primary care
14
7
Psychiatry
10
5
Unspecified
2
1
Practice setting
University/Academic medical center
147
76
Veterans Administration Hospital
19
10
Clinic
13
7
Solo private practice
6
3
Hospital
3
2
Nursing home/Long term care
3
2
Unspecified
2
1
Percentage of patients >65 years (%)
73.13
23.02
Years in clinical practice
19.42
11.56
Note. DO = Doctor of Osteopathic Medicine, NP = Nurse
Practioner, APRN = Advanced Practice Registered Nurse,
PA = Physician Assistant.
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Table 2
Frequency of Use and Utility of Diagnostic Tests (N = 193)
How often used
How useful
Test
M (SD)
M (SD)
Cognitive screening
4.59 (0.81)
4.10 (0.94)
Comprehensive cognitive testing
3.17 (1.29)
4.00 (1.17)
Structural neuroimaging
3.87 (1.23)
3.24 (1.16)
Metabolic neuroimaging
1.64 (0.73)
2.45 (1.30)
CSF analysis
1.56 (0.76)
2.16 (1.25)
Note. All values are on a 1-5 Likert-type scale, 1 (Not at all), 3 (Moderately), 5
(Very).
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Table 3
Diagnostic Confidence Ratings (N = 193)
Vignette
CSF Condition

Borderline
M (SD)

AD
M (SD)

CSF present
CSF absent

3.40 (0.81)
3.16 (0.72)

3.59b (0.79)
3.24b (0.80)

Normal CSF
3.28 (0.83)
3.55 (0.78)
Borderline CSF
3.25 (0.81)
3.38c (0.72)
a
AD CSF
3.67 (0.75)
3.86d (0.80)
No CSF
3.16 a (0.72)
3.24cd (0.80)
Note. “CSF present” encapsulates the three CSF conditions. All
values are on a 1-5 Likert-type scale of diagnostic confidence, 1
(Not at all), 3 (Moderately), 5 (Very).
Values that share subscripts are significantly different at the p <
.05 level.
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Table 4
Logistic Regression of Significant Predictors of Diagnostic Choice (AD Etiology versus
Unknown Etiology)
Predictor
Borderline vignette
Normal CSF group
Borderline CSF group
AD CSF group

B

SE B

Exp(B)

95% C.I. Exp(B)

-0.16
0.90
2.50

0.54
0.47
0.51

0.86
2.47
12.21***

0.30 - 2.48
0.98 - 6.22
4.50 - 33.17

AD vignette
Normal CSF group
-1.16
0.46 0.31*
0.13 - 0.78
Borderline CSF group
-0.10
0.43 0.91
0.39 - 2.12
AD CSF group
1.53
0.54 4.60**
1.61 - 13.14
Post-vignette informant measure 1.16
0.29 3.17***
1.81 - 5.56
Note. Nonsignificant predictors removed from logistic regression: Years in clinical practice,
percentage of patients over the age of 65, practice specialty, vignette diagnostic confidence.
*p < .05, ** p < .01, *** p < .001
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Table 5
Post-Vignette Ratings of Whether Clinical Information Increased or Decreased Diagnostic
Confidence, Full Sample and by CSF Condition (N = 193)
Clinical information
Collateral report
Normal CSF
Borderline CSF
AD CSF
No CSF

Borderline vignette
M (SD)
4.16 (0.73)
4.23 (0.70)
4.18 (0.72)
4.26 (0.88)
4.02 (0.64)

AD vignette
M (SD)
4.28 (0.67)
4.22 (0.73)
4.20 (0.70)
4.56 c (0.55)
4.17 c (0.63)

Functional status
4.02 (0.75)
4.10 (0.72)
Normal CSF
4.11 (0.67)
4.11 (0.74)
Borderline CSF
4.07 (0.84)
4.14 (0.73)
AD CSF
4.14 (0.74)
4.16 (0.75)
No CSF
3.83 (0.73)
4.02 (0.69)
Patient age
3.54 (0.73)
3.52 (0.72)
b
Normal CSF
3.36 (0.79)
3.35 d (0.67)
Borderline CSF
3.53 (0.69)
3.41e (0.72)
b
AD CSF
3.84 (0.72)
3.93 d,e,f (0.70)
No CSF
3.48 (0.66)
3.43f (0.68)
CSF informationa
3.21 (0.93)
3.36 (0.98)
Normal CSF
3.15 (0.91)
3.15h (1.01)
Borderline CSF
2.93g (0.72)
3.11i (0.78)
g
AD CSF
3.58 (1.03)
3.84hi (0.97)
Note. Headings reflect values for entire sample; subheadings reflect values
by CSF condition. All values are on a 1-5 Likert-type scale, 1 (Less
confident), 3 (Neither less nor more confident), 5 (More confident).
a
Those who did not receive CSF information were not asked a follow-up
question about it.
Values that share subscripts are significantly different at the p < .05 level.
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Normal CSF
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Borderline
vignette
AD vignette

Borderline CSF

CSF Education
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AD vignette

AD CSF

No CSF

CSF Education
Borderline
vignette
AD vignette

Figure 1. Randomization and procedural flow.
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Figure 2. Percentage of clinicians choosing diagnostic categories by CSF condition for the
borderline and AD vignettes. Adjusted standardized residuals, signifying difference from
expected chi-square distribution, are significant at the ***p < .001 level.
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Appendix A
CSF education document
Amyloid plaques and neurofibrillary tangles are the pathological hallmarks of
Alzheimer’s disease (AD). Amyloid beta peptide, most commonly the 42 amino acid form
(Aβ42) is the major component of amyloid plaques; neurofibrillary tangles are made primarily of
aggregated tau proteins, including tau phosphorylated at residue 181 (ptau181). Aβ42, total tau
protein and ptau181 can be detected in cerebrospinal fluid (CSF). Many studies have shown that
AD patients as a group have CSF with lower levels of Aβ42 and higher levels of tau and ptau181
than cognitively normal people. A ratio of tau/Aβ42 or ptau181/Aβ42 usually provides the best
sensitivity and specificity to discriminate Alzheimer’s disease from cognitively normal, but there
is overlap of values between groups. This may be in large part because about 30% of cognitively
normal people over the age of 65 have pathological and CSF changes typical of AD (Fagan et al.,
2007; Price and Morris, 1999; Price et al., 2009). Several studies have shown that cognitively
normal people whose CSF shows these changes are five-fold more likely than those without the
changes to develop AD in the next 3-4 years (Fagan et al., 2007). Thus, changes in CSF (reduced
levels of Aβ42 and increased levels of tau and ptau181) may be very specific for the brain
pathology of AD but can be seen in people who do not have the symptoms of AD; these people
are at higher risk of having AD in the future and may have “preclinical” or “presymptomatic”
AD.
Clinical testing for AD CSF biomarkers is available commercially from Athena
Diagnostics. Athena provides values of Aβ42, tau and ptau181 without reference ranges and
provides a normalized ratio of Aβ42 to total tau (called the AT index) and level of ptau to
discriminate patients with Alzheimer’s disease from those with etiologies for cognitive change.
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An AT index of less than 1.0 and P-tau concentration of > 61 pg/ml are suggestive of AD. They
note that there is some overlap between normal individuals and those with AD (e.g. AT index
0.8-2.0 and ptau 54-68 pg/ml are in a “borderline” range). Athena cites a sensitivity of 85-94%
and a specificity of 83-90% for this ratio, citing two studies (Hulstaert et al., 1999; Andreasen et
al., 2001).
For reference, we also provide CSF biomarker values observed in research participants
who had a clinical assessment at Washington University (Table 1) and values observed observed
in a subset of these research participants who had autopsy proven AD.

Table 1. CSF Biomarker Values in Research Participants at the Knight ADRC Comparing
Cognitively Normal Individuals (Clinical Dementia Rating (CDR) of 0) to Those Who Have Very
Mild or Mild AD (CDR 0.5 or 1).
No AD (n=90)
Mild AD (n=33)
Mean Standard Mean
Standard
deviation
deviation
Aβ42
567
207
434
211
tau
342
175
565
302
ptau181 62
26
86
45
Note: All values shown are in pg/ml. The data were aggregated and did not allow calculation of
ATI.
Table 2. CSF Biomarker Values in 29 Individuals with Autopsy Proven AD (unpublished data
from the Knight ADRC)
Mean
MIN MAX
(Standard
Deviation)
Aβ42
425 (171)
183 786
tau
574 (287)
156 1200
ptau181
84 (38)
25
192
ATI
0.54 (0.3)
0.12 1.58
Note: All values shown are in pg/ml.

MEDIAN
360
544
78
0.52
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Appendix B
Borderline vignette
A 73-year-old retired pilot comes to your office for routine follow-up with his son who
lives nearby and sees him several times per week. His son reports he is concerned about his
father’s memory. The son reports that his father has always been a little repetitious but now
might tell the same story within a day. He is more dependent on his calendar to keep track of
appointments, checking it several times per day. He might forget the details of some recent
events, but recalls events well “if it interests him.” He still drives but has been reluctant to drive
to his son’s new home. He still goes to church and plays golf with friends. He still does minor
home repairs but they take him longer. He is independent in activities of daily living. The patient
is not overly concerned about his memory, stating some things just aren't important to him
anymore. The patient and his son both report his mood is low sometimes, but he denies having
low mood most days for two weeks or more.
AD vignette
A 71-year-old retired real estate agent comes to your office. His wife is also your patient
and while you are seeing her she mentions she has some concerns about her husband’s
memory. She reports he has forgotten several appointments in the past year and often forgets
things she has told him. He recalls recent events but is less likely to recall the details. He is still
driving, but struggles to find less familiar places. He attends church but stopped serving as a
deacon last year because he was having difficulty making decisions; he still meets with retired
friends often. She noted that he takes longer to do home repairs and has taken several months to
put up shelves in the garage and they are not up to his usual standard. He is independent in his
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activities of daily living. The patient reports his wife is worried about his memory but that he has
not noticed any changes. They both denied low mood.
CSF values accompanying vignettes
Normal CSF: Aβ42 = 750 pg/ml
Total tau = 330 pg/ml
ptau181 = 40 pg/ml
ATI (Athena) =1.2
Borderline CSF: Aβ42 = 502 pg/ml
Total tau = 216 pg/ml
ptau181 = 60 pg/ml
ATI (Athena) = 1.0
AD CSF: Aβ42 = 300 pg/ml
Total tau = 619 pg/ml
ptau181 = 86 pg/ml
ATI (Athena) = 0.31
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